Call for Papers  

Article Details

Review Article

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists


Haowen Fang, Bing Niu* and Qin Chen   Pages 1 - 23 ( 23 )


Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short half-life of natural GLP-1 in vivo and can exist stably in patients for a long time, achieving good results in the treatment of diabetes, as well as improving the symptoms of some complications. The GLP-1 receptor agonists in the market are all peptide drugs. Compared with peptide drugs, small molecule agonists have the advantages of low cost and oral administration. In this article, we review the recent research progress of GLP-1 receptor agonists.


Type II diabetes, GLP-1, GLP-1R, peptide agonists, small molecule agonists, hypoglycemic drugs.


Read Full-Text article